165 related articles for article (PubMed ID: 31469704)
1. Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.
Peacock SH; James C; Turnbull MT; Cowart JB; Reid JM; Freeman WD
J Neurosci Nurs; 2019 Oct; 51(5):238-242. PubMed ID: 31469704
[TBL] [Abstract][Full Text] [Related]
2. Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
Hajizadeh Barfejani A; Rabinstein AA; Wijdicks EFM; Clark SL
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2155-2158. PubMed ID: 31103551
[TBL] [Abstract][Full Text] [Related]
3. Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics.
Vázquez-Medina A; Turnbull MT; James CL; Cowart JB; Lesser E; Carter RE; Ross OA; Miller DA; Meschia JF; De Jesús Espinosa A; Weinshilboum R; Freeman WD
Pharmacogenomics J; 2024 Jun; 24(4):19. PubMed ID: 38890281
[TBL] [Abstract][Full Text] [Related]
4. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.
Soppi V; Karamanakos PN; Koivisto T; Kurki MI; Vanninen R; Jaaskelainen JE; Rinne J
World Neurosurg; 2012 Jul; 78(1-2):101-9. PubMed ID: 22120252
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
[TBL] [Abstract][Full Text] [Related]
6. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
[TBL] [Abstract][Full Text] [Related]
7. Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients.
Cho S; Bales J; Tran TK; Korab G; Khandelwal N; Joffe AM
Ann Pharmacother; 2016 Sep; 50(9):718-24. PubMed ID: 27273676
[TBL] [Abstract][Full Text] [Related]
8. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Sandow N; Diesing D; Sarrafzadeh A; Vajkoczy P; Wolf S
Neurocrit Care; 2016 Aug; 25(1):29-39. PubMed ID: 26690937
[TBL] [Abstract][Full Text] [Related]
9. Nimodipine in Clinical Practice: A Pharmacological Update.
Clough B; Tenii J; Wee C; Gunter E; Griffin T; Aiyagari V
J Neurosci Nurs; 2022 Feb; 54(1):19-22. PubMed ID: 34775392
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.
Caylor MM; Macdonald RL
Neurocrit Care; 2024 Feb; 40(1):159-169. PubMed ID: 37740138
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry-based method for quantification of nimodipine and glutamate in cerebrospinal fluid. Pilot study with patients after aneurysmal subarachnoid haemorrhage.
Mindt S; Tokhi U; Hedtke M; Groß HJ; Hänggi D
J Clin Pharm Ther; 2020 Feb; 45(1):81-87. PubMed ID: 31421063
[TBL] [Abstract][Full Text] [Related]
12. Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
Samseethong T; Suansanae T; Veerasarn K; Liengudom A; Suthisisang C
Ann Pharmacother; 2018 Nov; 52(11):1061-1069. PubMed ID: 29783859
[TBL] [Abstract][Full Text] [Related]
13. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
[TBL] [Abstract][Full Text] [Related]
14. Investigational drugs for vasospasm after subarachnoid hemorrhage.
Tallarico RT; Pizzi MA; Freeman WD
Expert Opin Investig Drugs; 2018 Apr; 27(4):313-324. PubMed ID: 29600883
[TBL] [Abstract][Full Text] [Related]
15. Dangers of outpatient nimodipine use after spontaneous subarachnoid hemorrhage in accordance with the Comprehensive Stroke Center guidelines.
Chen CJ; Turnage C; Sokolowski JD; Kumar JS; Kalani MY; Park MS
J Clin Neurosci; 2018 Jun; 52():151-152. PubMed ID: 29656002
[TBL] [Abstract][Full Text] [Related]
16. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
van den Bergh WM; Mees SM; Rinkel GJ
Neurosurgery; 2006 Nov; 59(5):E1152; author reply E1152. PubMed ID: 17143226
[No Abstract] [Full Text] [Related]
17. Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage?
Hernández-Durán S; Mielke D; Rohde V; Malinova V
World Neurosurg; 2019 Dec; 132():e834-e840. PubMed ID: 31404696
[TBL] [Abstract][Full Text] [Related]
18. Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results.
Bele S; Proescholdt MA; Hochreiter A; Schuierer G; Scheitzach J; Wendl C; Kieninger M; Schneiker A; Bründl E; Schödel P; Schebesch KM; Brawanski A
Acta Neurochir (Wien); 2015 Dec; 157(12):2041-50. PubMed ID: 26439105
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
Isse FA; Abdallah YEH; Mahmoud SH
J Pharm Pharm Sci; 2020; 23(1):100-108. PubMed ID: 32348716
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage.
Smetana KS; Buschur PL; Owusu-Guha J; May CC
Crit Care Nurs Q; 2020; 43(2):138-156. PubMed ID: 32084059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
